Hydrazide containing nuclear transport modulators and uses thereof
Inventors
Sandanayaka, Vincent P. • Shacham, Sharon • McCauley, Dilara • Shechter, Sharon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I.or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Core Innovation
The invention relates to methods for treating a disorder associated with CRM1 activity by administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of a structural formula and a pharmaceutically acceptable carrier. The disclosed subject matter includes compounds represented by structural Formula I and related formulas, with variable substituents and acceptable salts and compositions.
The disclosure describes CRM1 (exportin-1/XPO1) nuclear transport modulators and nuclear transport inhibitors, including compounds with hydrazide-containing structures and Formula I-like compounds. The problem addressed is improper CRM1 activity and the need for CRM1 inhibition with improved pharmacokinetic characteristics, including higher exposure and low brain penetration or reduced brain-to-plasma outcome versus prior agents, including leptomycin B.
The methods and compositions encompass monotherapy and combination therapy, including administration of a second therapeutic agent. The disclosure further indicates use for treating, preventing, and diagnosing in vitro and in vivo and involving biological samples, and includes synthetic coupling routes and intermediate-to-product sequences for preparing compounds and related analogs.
Claims Coverage
The independent claim coverage centers on treating a disorder associated with CRM1 activity by administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of a structural formula and a pharmaceutically acceptable carrier. Across the provided claim sets, four recurring inventive features are identified, with dependent refinements directed to disorder subtype selection, oral administration, and combination therapy.
Treatment of a disorder associated with crm1 activity
A method for treating a disorder associated with CRM1 activity by administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of the structural formula and a pharmaceutically acceptable carrier.
Specific disorder subtypes
The treatment method is specified for myelodysplastic syndrome, multiple myeloma, and lymphoma.
Oral administration of the pharmaceutical composition
The method is practiced by orally administering the pharmaceutical composition.
Combination with a second therapeutic agent
The method further includes administering an effective amount of a second therapeutic agent.
The claim set is consistently directed to CRM1-associated disorder treatment using a structural-formula compound in a pharmaceutically acceptable carrier. Dependent coverage narrows the disorder to myelodysplastic syndrome, multiple myeloma, and lymphoma, and further includes oral administration and combination with a second therapeutic agent.
Stated Advantages
Improved pharmacokinetic performance is described via higher exposure, including AUC, AUCt, and AUCinf.
Low brain penetration or reduced brain-to-plasma outcome is described.
Support for CNS exposure is described in connection with BBB penetration.
Improved in vivo exposure with low brain penetration is described.
Documented Applications
Treating a disorder associated with CRM1 activity in a subject in need thereof.
Treating multiple myeloma.
Treating lymphoma.
Treating myelodysplastic syndrome.
Treating disorders associated with improper CRM1 activity, including cancers, inflammatory/immune disorders, viral infection, and neurodegenerative conditions.
TNBC xenograft efficacy and other cancer-related contexts.
CAIA arthritis.
A psoriasis model using PMA-induced psoriasis.
Preventing and diagnosing in the context of CRM1 inhibition, including use in vitro and in vivo and involving biological samples.
Administration as monotherapy and combination therapy with a second therapeutic agent for CRM1-mediated conditions.
Interested in licensing this patent?